# Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)

> **NCT04395092** · PHASE2 · WITHDRAWN · sponsor: **Kiadis Pharma**

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndromes (MDS)

## Interventions

- **BIOLOGICAL:** K-NK002
- **PROCEDURE:** Conditioning Regimen
- **PROCEDURE:** HaploBMT

## Key facts

- **NCT ID:** NCT04395092
- **Lead sponsor:** Kiadis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-11-13
- **Primary completion:** 2022-11
- **Final completion:** 2023-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor decided to withdraw this study
- **Last updated:** 2021-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04395092

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04395092, "Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04395092. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*